A study on the safety and effectiveness of photodynamic therapy with verteporfin in treating chronic focal or diffuse idiopathic central serous chorioretinopathy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-05000640

Enrollment

Unknown

Registered

2005-09-08

Start date

1990-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

two groups:photodynamic therapy versus placebo for 24 months vs observation

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Be aged 18 years or older VA with Snellen equivalent = 20/200 Fluorescein angiographic patterns of either Leakage area either in the subfoveal or juxtafoveal area Area of CNV >= 50% of the area of the total lesion Greatest linear dimension of the entire lesion must not exceed 5400 µm

Exclusion criteria

Exclusion criteria: Exclusion criteria: on exogenous corticosteroid systemic diseases such as Cushing's disease or renal diseases of glomerulonephritis pregnancy visual acuity worse than 20/200 in the affected eye myopia <= -6.00 diopters or other maculopathy tear (rip) of the retinal pigment epithelium a history of laser photocoagulation ocular surgery in the recent 3 months any contraindication for the verteporfin infusion or fluorescein injection

Design outcomes

Primary

Measure	Time frame
Visual acuity;	—

Secondary

Measure	Time frame
duration of subretinal fluid;	—

Countries

China

Contacts

Public ContactDr. Timothy Y.Y. Lai

eyeclinic@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026